DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Coleman RL, Brady MF, Herzog TJ. et al.
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol 2017;
18: 779-791
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.